Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 5151 entries
Sorted by: Best Match Show Resources per page
Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia.

Annals of gastroenterology

Tzamouranis D, Alexopoulou A, Dourakis SP, Stergiou GS.
PMID: 24713869
Ann Gastroenterol. 2012;25(3):254-257.

BACKGROUND: In cirrhotic patients awaiting liver transplantation, serum sodium concentration is related to prognosis. However, abnormalities in sodium homeostasis are evident even in the early preascitic stage of cirrhosis. We aimed to investigate whether parameters of renal sodium handling...

Cite
Tzamouranis D, Alexopoulou A, Dourakis SP, et al. Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia. Ann Gastroenterol. 2012;25(3):254-257
Tzamouranis, D., Alexopoulou, A., Dourakis, S. P., & Stergiou, G. S. (2012). Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia. Annals of gastroenterology, 25(3), 254-257.
Tzamouranis, Dimitris, et al. "Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia." Annals of gastroenterology vol. 25,3 (2012): 254-257.
Tzamouranis D, Alexopoulou A, Dourakis SP, Stergiou GS. Sodium handling is associated with liver function impairment and renin-aldosterone axis activity in patients with preascitic cirrhosis without hyponatremia. Ann Gastroenterol. 2012;25(3):254-257. PMID: 24713869; PMCID: PMC3959362.
Copy Download .nbib Format: NLM
Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'.

Diabetologia

Lambers Heerspink HJ, Johnsson E, Gause-Nilsson I, Sjöström C.
PMID: 26404064
Diabetologia. 2015 Dec;58(12):2901. doi: 10.1007/s00125-015-3765-7.

No abstract available.

Cite
Lambers Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'. Diabetologia. 2015;58(12):2901doi: 10.1007/s00125-015-3765-7.
Lambers Heerspink, H. J., Johnsson, E., Gause-Nilsson, I., & Sjöström, C. (2015). Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'. Diabetologia, 58(12), 2901. https://doi.org/10.1007/s00125-015-3765-7
Lambers Heerspink, H J, et al. "Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'." Diabetologia vol. 58,12 (2015): 2901. doi: https://doi.org/10.1007/s00125-015-3765-7
Lambers Heerspink HJ, Johnsson E, Gause-Nilsson I, Sjöström C. Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes'. Diabetologia. 2015 Dec;58(12):2901. doi: 10.1007/s00125-015-3765-7. PMID: 26404064.
Copy Download .nbib Format: NLM
Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept.

Blood pressure

Johnston CI.
PMID: 28425795
Blood Press. 2000;9:9-13. doi: 10.1080/080370500439155.

Angiotensin II type 1 (AT 1 ) receptor blockers, such as candesartan, are attractive alternatives to ACE inhibitors in the treatment of hypertension and cardiovascular disease. Although angiotensin-converting enzyme (ACE) inhibitors are able to suppress the renin-angiotensin system (RAS),...

Cite
Johnston CI. Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood Press. 2000;9:9-13doi: 10.1080/080370500439155.
Johnston, C. I. (2000). Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood pressure, 99-13. https://doi.org/10.1080/080370500439155
Johnston, Colin I. "Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept." Blood pressure vol. 9 (2000): 9-13. doi: https://doi.org/10.1080/080370500439155
Johnston CI. Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. Blood Press. 2000;9:9-13. doi: 10.1080/080370500439155. PMID: 28425795.
Copy Download .nbib Format: NLM
Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension.

Blood pressure

Trenkwalder P, Dahl K, Lehtovirta M, Mulder H.
PMID: 28425802
Blood Press. 2000;9:57. doi: 10.1080/080370500439308.

Microalbuminuria is a predictor of nephropathy in patients with type I or type II diabetes mellitus, and interventions that decrease albuminuria are likely to postpone the development of severe renal impairment. Suppression of the renin-angiotensin system by angiotensin-converting enzyme...

Cite
Trenkwalder P, Dahl K, Lehtovirta M, et al. Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood Press. 2000;9:57doi: 10.1080/080370500439308.
Trenkwalder, P., Dahl, K., Lehtovirta, M., & Mulder, H. (2000). Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood pressure, 957. https://doi.org/10.1080/080370500439308
Trenkwalder, P, et al. "Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension." Blood pressure vol. 9 (2000): 57. doi: https://doi.org/10.1080/080370500439308
Trenkwalder P, Dahl K, Lehtovirta M, Mulder H. Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension. Blood Press. 2000;9:57. doi: 10.1080/080370500439308. PMID: 28425802.
Copy Download .nbib Format: NLM
Comparative Analysis of .

Frontiers in plant science

Erill I, Puigvert M, Legrand L, Guarischi-Sousa R, Vandecasteele C, Setubal JC, Genin S, Guidot A, Valls M.
PMID: 28450872
Front Plant Sci. 2017 Apr 13;8:504. doi: 10.3389/fpls.2017.00504. eCollection 2017.

No abstract available.

Cite
Erill I, Puigvert M, Legrand L, et al. Comparative Analysis of . Front Plant Sci. 2017;8:504doi: 10.3389/fpls.2017.00504.
Erill, I., Puigvert, M., Legrand, L., Guarischi-Sousa, R., Vandecasteele, C., Setubal, J. C., Genin, S., Guidot, A., & Valls, M. (2017). Comparative Analysis of . Frontiers in plant science, 8504. https://doi.org/10.3389/fpls.2017.00504
Erill, Ivan, et al. "Comparative Analysis of ." Frontiers in plant science vol. 8 (2017): 504. doi: https://doi.org/10.3389/fpls.2017.00504
Erill I, Puigvert M, Legrand L, Guarischi-Sousa R, Vandecasteele C, Setubal JC, Genin S, Guidot A, Valls M. Comparative Analysis of . Front Plant Sci. 2017 Apr 13;8:504. doi: 10.3389/fpls.2017.00504. eCollection 2017. PMID: 28450872; PMCID: PMC5390034.
Copy Download .nbib Format: NLM
Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors.

The American journal of managed care

Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, Benton W, Golestaneh L.
PMID: 27668789
Am J Manag Care. 2016 Aug;22(11):s311-s324.

No abstract available.

Cite
Epstein M, Alvarez PJ, Reaven NL, et al. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016;22(11):s311-s324
Epstein, M., Alvarez, P. J., Reaven, N. L., Funk, S. E., McGaughey, K. J., Brenner, M. S., Benton, W., & Golestaneh, L. (2016). Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. The American journal of managed care, 22(11), s311-s324.
Epstein, Murray, et al. "Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors." The American journal of managed care vol. 22,11 (2016): s311-s324.
Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, Benton W, Golestaneh L. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2016 Aug;22(11):s311-s324. PMID: 27668789.
Copy Download .nbib Format: NLM
Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review.

International journal of clinical and experimental medicine

Xue J, Yu H, Yan J, Ren N, Yang Y, Wang X, Wang Y.
PMID: 26309699
Int J Clin Exp Med. 2015 Jun 15;8(6):10051-7. eCollection 2015.

A 55-year-old Chinese male was admitted to the hospital for epigastralgia and dysphagia with a two month history, and hematemesis and melena with a two-day history. Two lesions were found in the esophagus and stomach by esophago--gastroduodenoscopy and computed...

Cite
Xue J, Yu H, Yan J, et al. Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review. Int J Clin Exp Med. 2015;8(6):10051-7
Xue, J., Yu, H., Yan, J., Ren, N., Yang, Y., Wang, X., & Wang, Y. (2015). Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review. International journal of clinical and experimental medicine, 8(6), 10051-7.
Xue, Jinru, et al. "Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review." International journal of clinical and experimental medicine vol. 8,6 (2015): 10051-7.
Xue J, Yu H, Yan J, Ren N, Yang Y, Wang X, Wang Y. Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review. Int J Clin Exp Med. 2015 Jun 15;8(6):10051-7. eCollection 2015. PMID: 26309699; PMCID: PMC4538029.
Copy Download .nbib Format: NLM
Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned.

Therapeutic innovation & regulatory science

Sun H, Temeck JW, Chambers W, Perkins G, Bonnel R, Murphy D.
PMID: 28890858
Ther Innov Regul Sci. 2017;2017:1-7. doi: 10.1177/2168479017725558. Epub 2017 Aug 18.

BACKGROUND: "Complete Extrapolation" of efficacy from adult or other pediatric data, to the pediatric population, is an important scientific tool that reduces the need for pediatric efficacy trials. Dose finding and safety studies in pediatrics are still needed. "No...

Cite
Sun H, Temeck JW, Chambers W, et al. Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned. Ther Innov Regul Sci. 2017;2017:1-7doi: 10.1177/2168479017725558.
Sun, H., Temeck, J. W., Chambers, W., Perkins, G., Bonnel, R., & Murphy, D. (2017). Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned. Therapeutic innovation & regulatory science, 20171-7. https://doi.org/10.1177/2168479017725558
Sun, Haihao, et al. "Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned." Therapeutic innovation & regulatory science vol. 2017 (2017): 1-7. doi: https://doi.org/10.1177/2168479017725558
Sun H, Temeck JW, Chambers W, Perkins G, Bonnel R, Murphy D. Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned. Ther Innov Regul Sci. 2017;2017:1-7. doi: 10.1177/2168479017725558. Epub 2017 Aug 18. PMID: 28890858; PMCID: PMC5587157.
Copy Download .nbib Format: NLM
Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension.

EXCLI journal

Sen S, Gürel N, Ufuktepe B, Özünal ZG, Büyüklü Ç, Üresin Y.
PMID: 28507470
EXCLI J. 2017 Mar 10;16:245-255. doi: 10.17179/excli2016-725. eCollection 2017.

Renin Angiotensin Aldosterone System (RAAS) plays an important role in the development of hypertension. On the other hand, hypertension is a well-known and independent risk factor for cognitive impairment. The aim of the present study was to evaluate the...

Cite
Sen S, Gürel N, Ufuktepe B, et al. Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI J. 2017;16:245-255doi: 10.17179/excli2016-725.
Sen, S., Gürel, N., Ufuktepe, B., Özünal, Z. G., Büyüklü, �. �., & Üresin, Y. (2017). Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI journal, 16245-255. https://doi.org/10.17179/excli2016-725
Sen, Selçuk, et al. "Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension." EXCLI journal vol. 16 (2017): 245-255. doi: https://doi.org/10.17179/excli2016-725
Sen S, Gürel N, Ufuktepe B, Özünal ZG, Büyüklü Ç, Üresin Y. Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI J. 2017 Mar 10;16:245-255. doi: 10.17179/excli2016-725. eCollection 2017. PMID: 28507470; PMCID: PMC5427471.
Copy Download .nbib Format: NLM
Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients.

Archives of medical science : AMS

Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M.
PMID: 28507583
Arch Med Sci. 2017 Apr 01;13(3):652-658. doi: 10.5114/aoms.2017.66022. Epub 2017 Apr 20.

INTRODUCTION: About one quarter of human immunodeficiency virus (HIV) infected persons in Serbia have also been found to be hepatitis C virus (HCV) co-infected. In the general population, HCV genotype 1 has been shown to be the most prevalent...

Cite
Salemovic D, Pesic-Pavlovic I, Jevtovic D, et al. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13(3):652-658doi: 10.5114/aoms.2017.66022.
Salemovic, D., Pesic-Pavlovic, I., Jevtovic, D., Bojovic, K., Ranin, J., Brmbolic, B., & Stanojevic, M. (2017). Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Archives of medical science : AMS, 13(3), 652-658. https://doi.org/10.5114/aoms.2017.66022
Salemovic, Dubravka, et al. "Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients." Archives of medical science : AMS vol. 13,3 (2017): 652-658. doi: https://doi.org/10.5114/aoms.2017.66022
Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017 Apr 01;13(3):652-658. doi: 10.5114/aoms.2017.66022. Epub 2017 Apr 20. PMID: 28507583; PMCID: PMC5420631.
Copy Download .nbib Format: NLM
Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Camkurt MA, Gülpamuk G, Fındiklı E, Elve R.
PMID: 28449567
Clin Psychopharmacol Neurosci. 2017 May 31;15(2):181-183. doi: 10.9758/cpn.2017.15.2.181.

Venlafaxine is a serotonergic and noradrenergic reuptake inhibitor which is used for the treatment of depression. We report a case of galactorrhea in a patient with major depressive disorder after starting treatment with venlafaxine. In particular, we discuss the...

Cite
Camkurt MA, Gülpamuk G, Fındiklı E, et al. Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine. Clin Psychopharmacol Neurosci. 2017;15(2):181-183doi: 10.9758/cpn.2017.15.2.181.
Camkurt, M. A., Gülpamuk, G., Fındiklı, E., & Elve, R. (2017). Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 15(2), 181-183. https://doi.org/10.9758/cpn.2017.15.2.181
Camkurt, Mehmet Akif, et al. "Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 15,2 (2017): 181-183. doi: https://doi.org/10.9758/cpn.2017.15.2.181
Camkurt MA, Gülpamuk G, Fındiklı E, Elve R. Dose Dependent Course of Hyperprolactinemic and Normoprolactinemic Galactorrhea Induced by Venlafaxine. Clin Psychopharmacol Neurosci. 2017 May 31;15(2):181-183. doi: 10.9758/cpn.2017.15.2.181. PMID: 28449567; PMCID: PMC5426493.
Copy Download .nbib Format: NLM
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.

Kidney international

Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL.
PMID: 26376130
Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16.

Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin-angiotensin-aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium...

Cite
Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427-1433doi: 10.1038/ki.2015.270.
Bushinsky, D. A., Williams, G. H., Pitt, B., Weir, M. R., Freeman, M. W., Garza, D., Stasiv, Y., Li, E., Berman, L., & Bakris, G. L. (2015). Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney international, 88(6), 1427-1433. https://doi.org/10.1038/ki.2015.270
Bushinsky, David A, et al. "Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia." Kidney international vol. 88,6 (2015): 1427-1433. doi: https://doi.org/10.1038/ki.2015.270
Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16. PMID: 26376130; PMCID: PMC4678168.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 5151 entries